🇺🇸 FDA
Patent

US 11718591

Crystalline (2S,4R)-5-(5′-chloro-2′-fluoro-[1,1′-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2- methylpentanoic acid and uses thereof

granted A61KA61K31/415A61K45/06

Quick answer

US patent 11718591 (Crystalline (2S,4R)-5-(5′-chloro-2′-fluoro-[1,1′-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2- methylpentanoic acid and uses thereof) held by Theravance Biopharma R&D IP, LLC expires Mon Aug 03 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Theravance Biopharma R&D IP, LLC
Grant date
Tue Aug 08 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 03 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61K, A61K31/415, A61K45/06, A61K9/0053, A61K9/4816